Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich's conversation flits with ease from restaurants to solving the homeless crisis. His active mind has made him a serial inventor. But the founder and current CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, also has a razor-sharp focus when it comes to discussing his research. He wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. We've all seen it in elderly humans: Your grandparents are shrunken from their younger selves because their muscles no longer regenerate at the rate that they once did.

"When you go to the gym, you feel that burn which indicates that you have muscle damage. Your stem cells are responsible for repairing this damage and building your muscles," Watowich explains. Stem cells simply don't repair at the same rate in older individuals.

That's why, for example, elderly people who break a hip often fare poorly in the aftermath. It's not uncommon to face a difficult period of physical therapy following hip fracture surgery. Many patients do not return to independent living. And, the mortality rate one year after a hip fracture can be as high as 30 percent. If RLT-72484 proves to work as well in humans as it does in animal models, it could make it easier for patients to gain muscle after a fall.

But even for healthy older adults, muscle decline can cause problems. Travel is difficult if you don't have the muscle strength for long walks. Playing with grandchildren is a challenge if your mobility is compromised. Watowich's vision is to prevent muscle decline or at least slow it down.

The drug could also potentially help muscular dystrophy patients. The genetic diseases identified under that umbrella diagnosis all cause muscle loss before old age, sometimes even in infancy. If RLT-72484 fulfills its promise, it could allow MD patients to live more normal lives.

In the University of Texas Medical Branch study, the mice's muscle fiber doubled in size while muscle strength increased by 70 percent. The team published a study last month describing its results. The next year will be spent on studies necessary to win FDA approval to begin testing on humans.

Muscle loss isn't the only big problem Ridgeline Therapeutics is seeking to address. Obesity-linked diabetes is also in Watowich's sights. His team has come up with a small molecule that shrinks fat tissue in obese animals. In studies published last year, mice lost seven percent of their body weight in 10 days of treatment without changing their diets. The animals remained obese, but their fat deposits had decreased in size by 30 percent. The drug on its own cannot make obese people thin, but it may help diabetics to return to a non-diabetic state.

Ridgeline Therapeutics is based in the Texas Medical Center. Watowich explains that 98 percent of biotech companies fail, so it's his goal to "stay lean" and use the $4.2 million award the company received from the Department of Defense to get their technologies into human trials. The company will likely move to the Johnson & Johnson Innovation Labs collaboration space in the next few months.

But of course, what Ridgeline Technologies has to offer is most exciting of all. Remember, it's not going to allow you beat aging. But someday it may well help you to live without muscle loss or diabetes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

2 Houston space tech cos. celebrate major tech milestones

big wins

Two Houston aerospace companies — Intuitive Machines and Venus Aerospace — have reached testing milestones for equipment they’re developing.

Intuitive Machines recently completed the first round of “human in the loop” testing for its Moon RACER (Reusable Autonomous Crewed Exploration Rover) lunar terrain vehicle. The company conducted the test at NASA’s Johnson Space Center.

RACER is one of three lunar terrain vehicles being considered by NASA for the space agency’s Artemis initiative, which will send astronauts to the moon.

NASA says human-in-the-loop testing can reveal design flaws and technical problems, and can lead to cost-efficient improvements. In addition, it can elevate the design process from 2D to 3D modeling.

Intuitive Machines says the testing “proved invaluable.” NASA astronauts served as test subjects who provided feedback about the Moon RACER’s functionality.

The Moon RACER, featuring a rechargeable electric battery and a robotic arm, will be able to accommodate two astronauts and more than 880 pounds of cargo. It’s being designed to pull a trailer loaded with more than 1,760 pounds of cargo.

Another Houston company, Venus Aerospace, recently achieved ignition of its VDR2 rocket engine. The engine, being developed in tandem with Ohio-based Velontra — which aims to produce hypersonic planes — combines the functions of a rotating detonation rocket engine with those of a ramjet.

A rotating detonation rocket engine, which isn’t equipped with moving parts, rapidly burns fuel via a supersonic detonation wave, according to the Air Force Research Laboratory. In turn, the engine delivers high performance in a small volume, the lab says. This savings in volume can offer range, speed, and affordability benefits compared with ramjets, rockets, and gas turbines.

A ramjet is a type of “air breathing” jet engine that does not include a rotary engine, according to the SKYbrary electronic database. Instead, it uses the forward motion of the engine to compress incoming air.

A ramjet can’t function at zero airspeed, so it can’t power an aircraft during all phases of flight, according to SKYbrary. Therefore, it must be paired with another kind of propulsion, such as a rotating detonation rocket engine, to enable acceleration at a speed where the ramjet can produce thrust.

“With this successful test and ignition, Venus Aerospace has demonstrated the exceptional ability to start a [ramjet] at takeoff speed, which is revolutionary,” the company says.

Venus Aerospace plans further testing of its engine in 2025.

Venus Aerospace, recently achieved ignition of its VDR2 rocket engine. Photo courtesy of Venus Aerospace

METRO rolls out electric shuttles for downtown Houston commuters

on a roll

The innovative METRO microtransit program will be expanding to the downtown area, the Metropolitan Transit Authority of Harris County announced on Monday.

“Microtransit is a proven solution to get more people where they need to go safely and efficiently,” Houston Mayor John Whitmire said in a statement. “Connected communities are safer communities, and bringing microtransit to Houston builds on my promise for smart, fiscally-sound infrastructure growth.”

The program started in June 2023 when the city’s nonprofit Evolve Houston partnered with the for-profit Ryde company to offer free shuttle service to residents of Second and Third Ward. The shuttles are all-electric and take riders to bus stops, medical buildings, and grocery stores. Essentially, it works as a traditional ride-share service but focuses on multiple passengers in areas where bus access may involve hazards or other obstacles. Riders access the system through the Ride Circuit app.

So far, the microtransit system has made a positive impact in the wards according to METRO. This has led to the current expansion into the downtown area. The system is not designed to replace the standard bus service, but to help riders navigate to it through areas where bus service is more difficult.

“Integrating microtransit into METRO’s public transit system demonstrates a commitment to finding innovative solutions that meet our customers where they are,” said METRO Board Chair Elizabeth Gonzalez Brock. “This on-demand service provides a flexible, easier way to reach METRO buses and rail lines and will grow ridership by solving the first- and last-mile challenges that have hindered people’s ability to choose METRO.”

The City of Houston approved a renewal of the microtransit program in July, authorizing Evolve Houston to spend $1.3 million on it. Some, like council member Letitia Plummer, have questioned whether microtransit is really the future for METRO as the service cuts lines such as the University Corridor.

However, the microtransit system serves clear and longstanding needs in Houston. Getting to and from bus stops in the city with its long blocks, spread-out communities, and fickle pedestrian ways can be difficult, especially for poor or disabled riders. While the bus and rail work fine for longer distances, shorter ones can be underserved.

Even in places like downtown where stops are plentiful, movement between them can still involve walks of a mile or more, and may not serve for short trips.

“Our microtransit service is a game-changer for connecting people, and we are thrilled to launch it in downtown Houston,” said Evolve executive director Casey Brown. “The all-electric, on-demand service complements METRO’s existing fixed-route systems while offering a new solution for short trips. This launch marks an important milestone for our service, and we look forward to introducing additional zones in the new year — improving access to public transit and local destinations.”

———

This article originally ran on CultureMap.